胰腺导管腺癌发病率、治疗与生存的全国趋势
结果显示发病率由12.1升至15.3/10万,中位总生存由3.1个月升至3.8个月,切除率、辅助化疗与姑息化疗比例均上升;但多数患者仅接受支持治疗,整体生存获益有限。
要点
- PDAC发病率由12.1升至15.3/10万,中位总生存仅由3.1个月升至3.8个月。
- 切除率由8.3%升至16.6%,术后3年总生存由16.9%升至25.4%。
- 转移性疾病患者姑息化疗比例由5.3%升至16.1%,1年生存由13.3%升至21.2%。
核心结论
- 过去二十年PDAC发病率上升,切除率及辅助或姑息化疗使用增加并伴相应人群生存改善。
- 但全部PDAC患者的生存获益仅约3周,因多数患者仅接受支持治疗。
研究设计与样本
- 按治疗方式及诊断时期(1997-2000、2001-2004、2005-2008、2009-2012、2013-2016)分组。
- 采用Kaplan-Meier生存分析计算总生存。
主要发现
- 发病率从12.1(1997-2000)升至15.3(2013-2016)/10万(p < 0.001)。
- 中位总生存从3.1个月升至3.8个月(p < 0.001)。
- 切除率从8.3%升至16.6%(p-trend<0.001),术后3年总生存从16.9%升至25.4%(p < 0.001)。
- 辅助化疗比例从3.0%升至56.2%(p-trend<0.001)。
- 转移性疾病患者姑息化疗比例从5.3%升至16.1%(p-trend<0.001),1年生存从13.3%升至21.2%(p < 0.001)。
临床怎么用
- 提示PDAC诊治模式向积极切除与化疗转变,可参考其治疗比例变化评估本中心实践。
- 多数患者仍仅接受支持治疗,提示需加强姑息与支持治疗体系建设。
局限性
- 为登记处回顾性队列研究,治疗与生存趋势为群体层面关联,未提供随机对照证据。
- 摘要未报告合并症、体能状态及具体化疗方案等影响预后的个体因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC. MATERIALS AND METHODS: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplan-Meier survival analysis was used to calculate overall survival. RESULTS: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p < 0.001), whereas median overall survival increased from 3.1 to 3.8 months (p < 0.001). Over time, the resection rate doubled (8.3%-16.6%, p-trend<0.001), more patients received adjuvant chemotherapy (3.0%-56.2%, p-trend<0.001) and 3-year overall survival following resection increased (16.9%-25.4%, p < 0.001). Over time, the proportion of patients with metastatic disease who received palliative chemotherapy increased from 5.3% to 16.1% (p-trend<0.001), whereas 1-year survival improved from 13.3% to 21.2% (p < 0.001). The proportion of patients who only received supportive care decreased from 84% to 61% (p-trend<0.001). CONCLUSION: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care.
引用
- Latenstein AEJ, van der Geest LGM, Bonsing BA, et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2019. PMID: 31841792. doi:10.1016/j.ejca.2019.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。